FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely endocrinology, and can be used to predict the effectiveness of treating liraglutide in a patient suffering from obesity without type 2 diabetes mellitus. Patient's body weight and fasting plasma ghrelin level are measured before initiation of treatment with liraglutide to determine probability (p) of clinical effectiveness by formula:
,
where: A - initial weight, kg, B - initial level of ghrelin, fmole/ml. If probability > 50% is obtained, treatment with liraglutide will be effective.
EFFECT: method enables predicting the clinical effectiveness of obesity-free patients with type 2 diabetes mellitus even before the beginning of the therapy with using a glucagon-like peptide-1 liraglutide receptor agonist 3 mg, which can be achieved in 3 months after using this preparation, by determining prognostic criteria: measuring patient's body weight and determining the level of active ghrelin of plasma with subsequent determination of the clinical effectiveness by an equation obtained using a multifactor logit-regression model.
1 cl, 2 dwg, 3 tbl, 2 ex
